GlassScriptPhysician profile
Robert R Witham
NPI 1649296971
$2,189.02
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $290 · 2021: $424 · 2022: $144 · 2023: $39.00 · 2024: $76.72 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $559.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $194.94 | 2019-2022 | |
| Janssen Biotech, INC. | $168.58 | 2019-2021 | |
| Amgen INC. | $158.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $132.43 | 2019-2024 | Enhertu, Lokelma |
| Madrigal Pharmaceuticals | $128.57 | 2025 | Rezdiffra |
| Pharmacyclics LLC, An Abbvie Company | $100.69 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $94.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.24 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.32 | 2019-2024 | Eohilia |
| Abbvie INC. | $62.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.87 | 2019-2020 | |
| Astellas Pharma US INC | $56.09 | 2019-2020 | |
| Amarin Pharma, INC. | $49.18 | 2020 | |
| Genzyme Corporation | $45.51 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $42.75 | 2019 | |
| Ucb, INC. | $36.49 | 2019 | |
| Novocure INC. | $31.42 | 2019 | |
| Daiichi Sankyo INC. | $22.91 | 2019 | |
| Sandoz INC. | $21.58 | 2025 | Jubbonti |
| Sanofi-Aventis U.S. LLC | $21.51 | 2020 | |
| Pfizer INC. | $19.43 | 2019 | |
| Braintree Laboratories, INC. | $18.84 | 2019 | |
| Taiho Oncology, INC. | $18.40 | 2019 | |
| Celgene Corporation | $16.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Witham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.